Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial

David Cameron, Michelle Casey, Cristina Oliva, Beth Newstat, Bradley Imwalle, Charles E Geyer

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

A planned interim analysis of study EGF100151 prompted early termination of enrollment based on a longer time to progression with lapatinib and capecitabine than with capecitabine alone in patients with human epidermal growth factor receptor (HER)-2(+) previously treated advanced breast cancer or metastatic breast cancer (MBC). Here, we report final analyses of overall survival.
Original languageEnglish
Pages (from-to)924-34
Number of pages11
JournalThe Oncologist
Volume15
Issue number9
DOIs
Publication statusPublished - 2010

Keywords / Materials (for Non-textual outputs)

  • Breast cancer
  • Lapatinib
  • Metastatic
  • Capecitabine
  • Survival
  • HER-2

Fingerprint

Dive into the research topics of 'Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial'. Together they form a unique fingerprint.

Cite this